BioCentury
ARTICLE | Company News

Alexion, Austin Research Institute deal

February 22, 2000 8:00 AM UTC

The partners modified a 1998 licensing agreement by returning to Austin the right to commercialize products associated with Austin’s alpha1,3 galactosyltransferase patent to prevent hyperacute rejection in organ and pancreatic islet xenotransplantation. ALXN retains commercialization rights in cell and tissue xenotransplantation. Under the original agreement, ALXN received exclusive worldwide rights to the patent (see BioCentury, Oct. 19, 1998). ...